Topic Listing for 3SBio

A-b2 Inflation A11 Continuing Pricing Pressure
A12 Tpiao Growth Reduced Reliance Epiao Sales A13 Chinese Government Undertaking Comprehensive Health Care Reform
A14 Possible Adverse Effects Global Economic Crisis A15 Preferential Tax Status Secured
Access Corporate Governance Policies Accounting Foreign Exchange Impact Assets Liabilities
Accounts Receivable Accounts Receivable Net
Accrued Expenses Other Payables Acquire In-license New Technologies Products Companies
Address Principal Executive Offices Administrative Protection Monitoring Periods New Drugs
Adverse Changes Political Economic Other Policies Chinese Government Advertising Research Development Costs
Agreements Epitomics Inc Allowance Doubtful Accounts
Amag Pharmaceuticals Inc American Depositary Shares
Amounts Due Related Parties Follows Annual Report Shareholders
Anti-corruption Measures Taken Government Authorities Correct Corruptive Practices Anti-corruption Measures Taken Government Correct Corruptive Practices Pharmaceutical
Applicable Other Disclosures Approval Licenses Pre-filled Syringe Epiao Products
Articles Association Contain Anti-takeover Provisions Adversely Affect Rights Audit Committee
Available-for-sale Securities B10 Employees
B11 Regulations B11-a Regulatory Authorities
B11-b1 Drug Administration General B11-b2 Medicine Approval Manufacturing
B11-b3 Distribution B11-b4 Key Certificates Permits
B11-b5 Consumer B11-c1 Prc Patent Law
B11-c2 Trademarks B11-c3 Administrative Protection Monitoring Periods New Drugs
B11-d Prc Enterprise Income Tax B11-e Regulation Foreign Currency Exchange Dividend Distribution Overseas
B11-f Other National Provincial Level Laws Regulations B12 Legacy Products
B13 In-licensed Products B15 Product Pipeline
B21 Export Sales B81 Quality Control Assurance
Basis Presentation Board Practices
Business Benefits Certain Government Incentives Expiration Change Material Business Benefits Certain Tax Other Government Incentives Expiration
Business Cooperation Agreement Business Cooperation Agreements
Business Credit Concentrations Business Depends Shenyang Sunshine Epiao Brands Not Able
Business Development Business Highlights
C21 Consolidation Vie Treatment Capital Commitments
Capital Expenditures Cash Equivalents
Cayman Islands Because Judicial Precedent Regarding Rights Shareholders Cayman Islands British Virgin Taxes
Cayman Islands Tax Cayman Islands Taxation
Certain Agreements Vie Entities Certain Raw Materials Medical Devices Components Single-sourced Parties
Certificates Permits Certification
Certification Chief Executive Officer Certification Chief Financial Officer
Changes Internal Controls Changes Internal Controls Over Financial Reporting
Changes Prc Government Policy Foreign Investment China Adversely Chief Financial Officer
Chinas Accession World Trade Organization Wto Intensify Competition Chinas Accession Wto Intensify Competition Pharmaceutical Industry China
Classification Documents Classified Passive Foreign Investment United States Federal Income
Commercial Success Products Depends Degree Market Acceptance Among Commitments Contingencies
Compared 2005 Compared 2006
Compared 2007 Compared 2008
Compensation Compensation Committee
Competition Competition Principal Markets
Competitors Ability Manufacture Pharmaceutical Products Substantially Similar Ours Compliance Committee Reporting
Compulsory License Conference Call
Confidentiality Conflicts Interest
Consent Independent Registered Public Accounting Firm Consolidated Financial Statements
Consolidation Beijing Sunshine Liaoning Vies Consolidation Variable Interest Entities
Contact Continue Expand Beyond Chinese Domestic Market
Continuing Pricing Pressure Contractual Arrangements Beijing Sunshine Bio-product Sales Liaoning Pharmaceutical
Contractual Arrangements Beijing Sunshine Bio-product Sales Liaoning Respective Contractual Arrangements Liaoning Sunshine Beijing
Contractual Arrangements Liaoning Sunshine Shareholders Not Effective Providing Conventions
Corporate Boards Corporate Guarantees
Corporate History Corporate Information
Corporate Opportunities Cost Net Revenues
Cost Revenues Critical Accounting Policies Estimates
Currency Convenience Translation Currently Conduct Certain Sales Activities Through Liaoning Sunshine
Currently Conduct Sales Activities Through Liaoning Sunshine Beijing Currently Dependent Flagship Product Epiao Reduction Revenues Cause
Customer Supplier Concentration Dan Lou Chairman His Son Jing Chief Executive
Date Relevance Update Deferred Grant Income
Definitions Depend Administrative Protection Monitoring Periods Certain Products Afford
Depend Distributors Sales Products Depreciation
Determination Other-than-temporary Impairment Investment Securities Develop Commercialize Candidates Product Pipeline New Products Address
Develop Commercialize Ferumoxytol China Difficulties Seeking Recognition Enforcement Foreign Judgments China
Directors Nominated Election Annual General Meeting Directors Senior Officers Share Ownership
Disclosure Code Disclosure Confidential Corporate Information
Discussion Certain Change Disposal Interest Beijing Sunshine Liaoning
Dispositions Adss Ordinary Shares Distribution Pharmaceutical Products
Distributions Adss Ordinary Shares Diverse Portfolio Marketed Products Product Candidates Targeting Nephrology
Dividend Distribution Dividend Policy
Dividends Documents Display
Drug Administration Laws Regulations Duties Directors
Early Stage Products Economic Control Arrangements
Election Directors Employee Participation Capital 2006 Stock Incentive Plan
Employees Employment Agreements
Employment Agreements Director Services Appointment Employment Outside Personal Business Activities
English Translation Purchase Contract Form Epiao
Equity Pledge Agreement Equity Pledge Agreements
Estimated Useful Lives Impairment Long-lived Assets Estimates
Evaluation Disclosure Controls Procedures Examination Approval New Medicines
Exchange Controls Exchange Rate Information
Exchange Rate Volatility Adversely Affect Competitive Position Financial Executive Officers Directors
Expand Sales Marketing Network Experience Significant Period-to-period Quarterly Annual Fluctuations Revenues Operating
Experienced Market-oriented Management Team Expiration Changes Tax Incentives Material Adverse Effect Operating
Explanatory Export Sales
Export Sales Expose Risks Uncertainties Liabilities Related Destination Export Sales While Accounted Small Percentage Total Revenues
Face Risks Related Health Epidemics Outbreaks Contagious Diseases Facilities
Fail Achieve Maintain Effective Internal Controls Fail Achieve Specified Conditions Such Sales Goals Respect
Fail Achieve Specified Sales Goals Respect In-licensed Product Failure Achieve Maintain Effective Internal Controls Material Adverse
Failure Implement Growth Expansion Strategy Result Deterioration Results Fair Value Financial Instruments
Fasb Interpretation Fin Federal Income Tax Considerations Persons
Ferumoxytol Filing 20f
Financial Highlights Financial Results
Financial Statements Financing History
Foreign Currency Exchange Foreign Currency Risk
Foreign Currency Transactions Fraud Similar Irregularities
Fsp 142-3 Fsp Fas 115-2 124-2
Fsp Fas 157-4 Full 2009 Guidance
Full Guidance Full Guidance Selected Objectives
Future Capital Needs Uncertain Result Need Raise Additional Future Changes Laws Regulations Enforcement Policies China Adversely
General Government Grants
Guarantees Half 2008 Financial Highlights
Half 2009 Financial Highlights Health Insurance System
Held 2008 High-dosage Epiao
High-dose Epiao High-quality Proprietary Manufacturing Processes Significant Cost Advantages
Highly Dependent Senior Management Key Research Development Personnel Holders Adss Fewer Less Rights Shareholders Act Through
Holders Adss Fewer Rights Shareholders Act Through Depositary Immediate Release
Impairment Long-lived Assets In-licensed Products
Income Before Tax Expense Minority Interests Result Foregoing Income Per Share
Income Taxes Independent Auditor
Index Consolidated Financial Statements Information Reporting Backup Withholding
Insider Trading Intellectual Property
Interest Rate Risk Internal Accounting Controls
International Patent Treaties International Toll Dial-in 65-6735-7955 Replay- Conference 38479039
Introduction Inventories
Inventories Allowance Obsolescence Investment Committee
Investment Securities Law
Leading Market Share Epo China Lease Prepayments
Legacy Products Legal Compliance
Legal Proceedings Liaoning Sunshine Beijing Previously Engaged Activities Without Necessary
Limited Amendment List Subsidiaries 3sbio Inc Registrant
Lloyds Investment Loss Major Shareholders
Management Commentary Outlook Manufacturing
Market Price Adss Volatile Market Risk Management
Marketing Sales Distribution Markets
Material Contracts Material Modifications Rights Security Holders Proceeds
Maximize Sales Lead Product Epiao Chinese Market Maximize Sales Other Existing Products Nephrology Oncology Markets
Memorandum Articles Association Miscellaneous
Nationwide Sales Marketing Network Net Cash Provided Operating Activities
Net Cash Provided Used Financing Activities Net Cash Provided Used Investing Activities
Net Cash Used Financing Activities Net Revenues
New Product Development Pharmaceutical Industry Costly Labor-intensive Low Non-current Deposits
Non-gaap Financial Measures Reconciliation Gaap Not Able Commercialize Product Candidates Preclinical Studies Produce
Not Achieve Projected Development Goals Time Frames Announce Notes Reconciliation Gaap Statements Income Adjusted
Notes Reconciliation Gaap Statements Income Non-gaap Nuleusin
Nuleusin Il-2 Nupiao
Off-balance Sheet Arrangements Offer Listing Details
Operating Expenses Operating Lease Commitments
Operating Officer Operational Efficiency Track Record Growth Profitability
Operations Subject Uncertainty Associated Legal System China Adversely Operations Subject Uncertainty Associated Legal System China Limit
Option Grant Directors Senior Officers Ordinary Shares Par Value Us00001
Ordinary Shares Par Value Us00001 2007 Ordinary Shares Par Value Us00001 2008
Organizational Structure Other Change Qualified
Other Income Expense Net Other Matters
Other National Provincial Level Laws Regulations Overall Business Performing Expected Strong Set Results Reiterate
Overview Part
Passive Foreign Investment Patent Enforcement
Patent Prosecution Payments Gifts
Pension Other Postretirement Benefits Permits Licenses Manufacturing Registration Drugs
Personal Financial Interests Pharmaceutical Industry China Highly Regulated Future Government Regulation
Pharmaceutical Industry Extremely Competitive Phase Data
Phase Products Phase Program Updates
Phase Programs Update Phase Study
Power Shortages Natural Disasters Terrorist Acts Other Calamities Prc Legal Risks Uncertainties
Prc Patent Law Preliminary 2008 Selected Financial Results
Prepaid Expenses Other Receivables Prescription Regulations
Price Control Price Control Competitive Bidding
Pricing Products Subject Government Approval Changes Control Prices Principal Activities
Principal Affiliated Entities Principal Capital Expenditures Divestures
Principal Products Principal Related Party Transactions Follows
Principal Shareholder Liaoning Sunshine Potential Conflicts Interest Adversely Principles Consolidation
Product Liability Product Pipeline
Product Portfolio Products Face Substantial Competition Not Able Compete Effectively
Products Face Substantial Competition Other Companies Discover Develop Products Infringe Intellectual Property Rights Parties Incur Substantial
Property Plant Equipment Property Plant Equipment Net
Protection Assets Proven Research Development Capabilities
Provides 2009 Net Revenue Guidance Range Us43-us45 Proxy Properly Executed Voted Manner Directed Herein Undersigned
Purchase Agreements Acquisition Equity Interest Liaoning Sunshine Purchase Agreements Acquisition Equity Interests Liaoning Sunshine Beijing
Purchase Contract Purpose
Pursuant 302 Sarbanes-oxley Act 2002 Pursuant 906 Sarbanes-oxley Act 2002
Pursue Collaborations In-licensing Arrangements Acquisitions Other Strategic Initiatives Quality Control Assurance
Quantitative Qualitative Disclosures Market Risk Rapid Changes Pharmaceutical Industry Render Products Obsolete
Ratification Independent Registered Public Accountants Receive Approval Mofcom Before Purchase Equity Interests Liaoning
Recent Global Economic Crisis Slowdown Chinese Economy Materially Recent Issued Accounting Standards
Recently Issued Accounting Standards Reconciliation Gaap Adjusted Non-gaap
Record Date Share Ownership Quorum Regulation Foreign Currency Exchange Dividend Distribution
Regulation Foreign Exchange Certain Onshore Offshore Transactions Regulation Overseas Listings
Regulations Reimbursement National Medical Insurance Program
Related Party Transaction Related Party Transactions
Reorganization Replay
Report Independent Registered Public Accounting Firm Report Management Internal Control Over Financial Reporting
Reporting Potential Conflicts Interest Required Defend Lawsuits Pay Damages Product Liability Claims
Research Development Research Development Costs
Restrictions Currency Exchange Limit Ability Receive Revenues Effectively Restrictions Foreign Ownership Pharmaceutical Wholesale Retail Businesses
Results Results Operations
Retirement Other Postretirement Benefits Revenue Grows 237 Year-over-year Rmb686 Us100 Operating Income
Revenue Guidance Revenue Recognition
Revenues Revenues Denominated Renminbi Not Freely Convertible Capital Account
Revenues Denominated Renminbi Subject Exchange Rate Volatility Revocability Proxies
Right Participate Future Rights Offerings Limited Cause Dilution Risk Factors
Risk Uncertainties Residency Rmb Expressed
Rmb Expressed Except Per Share Data Rmb Expressed Except Share Data
Safe Harbor Safe Harbor Statement
Sbio Inc Sbio Inc Announces 2007 Results
Sbio Inc Announces 2008 Results Sbio Inc Announces Change Board Directors
Sbio Inc Announces Preliminary 2008 Results Sbio Inc Announces Results Annual General Meeting
Sbio Inc Appoints Tan Chief Financial Officer Sbio Inc Approves Share Repurchase Program
Sbio Inc Files Sfda Approval High-dose 36000 Epiao Sbio Inc Files Sfda Approval Nuleusin
Sbio Inc Hold Annual General Meeting Securities Exchange Staff Accounting Bulletin 108 Sab
Securities Registered Pursuant Act Segment Reporting
Selling Prices Products Tend Decline Over Time Success Sfas 157
Sfas 159 Sfas 160
Sfas 161 Share Capital
Share Repurchase Program Share-based Compensation
Share-based Compensation Expenses Share-based Payments
Shares Granted Executives Signatures
Significant Changes Significant Trends Developments Factors
Sss07 Rheumatoid Arthritis Other Autoimmune Diseases Sss08 Hpv Vaccine
Statement Regarding Financial Information Statutory Public Welfare Fund
Statutory Reserves Statutory Safe Harbor
Statutory Surplus Reserve Stock Option Plan
Strategy Structured Deposit
Subject Environmental Regulations Exposed Liability Potential Costs Compliance Subject Limitations Transfers Adss
Subject Risks Uncertainties Assumptions Subsidiary Information
Supply Raw Material Table Contents
Tabular Disclosure Contractual Obligations Tax Residency
Taxes Incentives Terms Directors Executive Officers
Threshold Pfic Classification Matters Tpiao
Tpiao Itp Tpiao Phase Studies
Tpiao Treatment Itp Trademarks
Treatment Itp Trend Information
Unable Protect Products Through Intellectual Property Rights Competitors United States Federal Income Tax Considerations Persons
Us38 Reiterates Fy2009 Revenue Guidance Vat
Voting Agreement Voting Agreements
Voting Holders American Depositary Shares Voting Holders Ordinary Shares
Voting Solicitation Webcast
What Forward-looking Statements Working Place
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki